Literature DB >> 2506953

Four new recurring translocations in non-Hodgkin lymphoma.

E G Levine1, D C Arthur, J Machnicki, G Frizzera, D Hurd, B Peterson, K J Gajl-Peczalska, C D Bloomfield.   

Abstract

The identification of recurring chromosomal translocations has provided clues to the gene regions important in lymphoma development. Among 157 patients with non-Hodgkin lymphoma studied by cytogenetic analysis, four new recurring translocations have been identified--t(8;9) (q24;p13), t(11;18)(q21;q21), t(14,15)(q32;q15), and an unbalanced translocation giving rise to der(22)t(17;22) (q11;p11). Each translocation appeared twice. The t(11;18) was the only karyotypic abnormality in the two patients with it, and the t(14;15) was the sole karyotypic abnormality in one patient. All translocations were found in B-cell malignancies and were associated with both nodal and extranodal disease. Among the regions affected, only the immunoglobulin heavy-chain gene MYC, and BCL2, have thus far been associated with lymphoma. The breakpoint sites identified by these translocations warrant further investigation at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506953

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas.

Authors:  A Rosenwald; G Ott; S Stilgenbauer; J Kalla; M Bredt; T Katzenberger; A Greiner; M M Ott; B Gawin; H Döhner; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Trisomy 3 is not a common feature in malignant lymphomas of mucosa-associated lymphoid tissue type.

Authors:  G Ott; J Kalla; A Steinhoff; A Rosenwald; T Katzenberger; U Roblick; M M Ott; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 3.  From MALT lymphoma to the CBM signalosome: three decades of discovery.

Authors:  Shaun Rosebeck; Aasia O Rehman; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

4.  API2-MALT1 fusion transcripts involved in mucosa-associated lymphoid tissue lymphoma: multiplex RT-PCR detection using formalin-fixed paraffin-embedded specimens.

Authors:  H Inagaki; M Okabe; M Seto; S Nakamura; R Ueda; T Eimoto
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 5.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 6.  The Paracaspase MALT1.

Authors:  Janna Hachmann; Guy S Salvesen
Journal:  Biochimie       Date:  2015-09-16       Impact factor: 4.079

7.  Identification of Evi-3, a novel common site of retroviral integration in mouse AKXD B-cell lymphomas.

Authors:  M J Justice; H C Morse; N A Jenkins; N G Copeland
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Cytogenetic findings in 175 patients indicate that items of the Kiel classification should not be disregarded in the REAL classification of lymphoid neoplasms.

Authors:  H Nowotny; H Karlic; H Grüner; J Hirsch; M Vesely; A Nader; R Heinz
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

9.  Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways.

Authors:  Ellen D Remstein; Paul J Kurtin; C David James; Xiao-Yang Wang; Reid G Meyer; Gordon W Dewald
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.

Authors:  Stephen M Ansell; Takashi Akasaka; Ellen McPhail; Michelle Manske; Esteban Braggio; Tammy Price-Troska; Steven Ziesmer; Frank Secreto; Rafael Fonseca; Mamta Gupta; Mark Law; Thomas E Witzig; Martin J S Dyer; Ahmet Dogan; James R Cerhan; Anne J Novak
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.